Core Insights - Plus Therapeutics has received approval for a new Category III CPT code from the American Medical Association to track the utilization of convection-enhanced delivery (CED) for REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer, marking a significant step towards market access and commercialization [1][2] Group 1: REYOBIQ Therapy - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [3] - The therapy is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions, including a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [3] Group 2: Market Access and Utilization Tracking - The approved Category III CPT code, X566T, will facilitate the tracking of CED procedures for REYOBIQ, aiding in the evaluation of its clinical use and supporting future reimbursement and coverage decisions [2] - The new CPT code will be published on July 1, 2026, and will take effect for reporting on January 1, 2027, which is expected to enhance the adoption of REYOBIQ in clinical settings [2] Group 3: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging CNS cancers, aiming to improve clinical outcomes through innovative treatment approaches [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Insights - Rhenium (Re) Obisbemeda shows promising safety and efficacy for glioblastoma patients, with a median overall survival of 17 months for those receiving doses greater than 100 Gy, compared to 8 months with standard care [1][7] - The publication of Phase 1 trial results in a high-impact journal validates the clinical program and supports the ongoing ReSPECT-GBM Phase 2 trial [2] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, particularly recurrent glioblastoma and leptomeningeal metastases [9] - The company utilizes advanced platform technologies to enhance patient outcomes through targeted drug delivery and image-guided local beta radiation [9] Clinical Trial Details - The ReSPECT-GBM trial is currently enrolling patients and aims to provide a much-needed treatment option for recurrent glioblastoma, which has limited existing therapies [2][3] - Rhenium (Re) Obisbemeda is being evaluated in clinical trials, including ReSPECT-GBM and ReSPECT-LM, with significant funding support from the National Cancer Institute and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [5] Disease Context - Glioblastoma affects approximately 15,000 patients annually in the U.S. and is characterized by a poor prognosis, with an average life expectancy of less than 24 months [4] - Current treatments for recurrent glioblastoma offer marginal survival benefits and are associated with significant side effects, highlighting the need for more effective therapies [4] Treatment Mechanism - Rhenium (Re) Obisbemeda is a novel injectable radiotherapy designed to deliver high doses of targeted radiation directly to CNS tumors, potentially improving outcomes compared to existing therapies [5] - The treatment utilizes Rhenium-186, which has a short half-life and is effective for both destroying cancerous tissue and real-time imaging [5]